Atria Wealth Solutions Inc. Sells 7,494 Shares of Bristol-Myers Squibb (NYSE:BMY)

Atria Wealth Solutions Inc. reduced its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 187,645 shares of the biopharmaceutical company’s stock after selling 7,494 shares during the period. Atria Wealth Solutions Inc.’s holdings in Bristol-Myers Squibb were worth $9,628,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Capital Advisors Ltd. LLC raised its position in Bristol-Myers Squibb by 6.6% in the 4th quarter. Capital Advisors Ltd. LLC now owns 8,435 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 519 shares during the period. Wynn Capital LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter worth $232,000. Bfsg LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter worth $46,000. Financial Perspectives Inc raised its position in Bristol-Myers Squibb by 28.0% in the 4th quarter. Financial Perspectives Inc now owns 1,066 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 233 shares during the period. Finally, GAMMA Investing LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter worth $639,000. 76.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BMY has been the topic of a number of analyst reports. Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. Finally, William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $61.18.

Bristol-Myers Squibb Stock Down 8.5 %

Shares of NYSE:BMY traded down $4.14 during trading on Thursday, reaching $44.72. 25,784,518 shares of the stock traded hands, compared to its average volume of 15,646,563. Bristol-Myers Squibb has a 52-week low of $44.61 and a 52-week high of $69.74. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. The stock has a 50-day moving average of $51.22 and a two-hundred day moving average of $51.31. The stock has a market cap of $90.64 billion, a P/E ratio of 11.70, a price-to-earnings-growth ratio of 1.48 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same quarter last year, the company posted $2.05 earnings per share. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 6.63 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 5.37%. Bristol-Myers Squibb’s payout ratio is presently 62.18%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.